Imclone--hier hilft wohl nur ein Call
| eröffnet am: | 14.02.04 18:13 von: | big lebowsky |
| neuester Beitrag: | 24.04.21 23:38 von: | Jenniferuoqra |
| Anzahl Beiträge: | 130 | |
| Leser gesamt: | 16003 | |
| davon Heute: | 3 | |
bewertet mit 0 Sternen |
||
|
|
||
M.E alles Kinderpost,wenn man die Umsätze und Möglichkeiten von EBITRUX bedenkt.Im ARIVA Forum steht etwas. Z.B. das EBITRUX für verschiedene Krebstherapien zur Anwendung kommen kann.
Ich habe da so ein Gefühl für ein Buy Out.Brystol könnte es machen.Also abwarten und Tee trinken. Ohne Zulassung war die Aktie schon im 60er bis 80er Bereich. Jetzt im 40er. Trotz aller Skandale um Imclone und Waksahl bzw. Maria Stewart; irgendetwas ist da im Busch.
Ciao B.L.
die pessimistischten analysten haben kursziele von 75 $, die optimisten immer noch über 100.
also befürchte ich, da ist mehr im busch, was wir leider nicht mitbekommen. denn der markt hat ja bekanntlich immer recht.
WÜRG!
Imclone (Nachrichten) wurde von Smith Barney von "buy" auf "hold" herabgestuft. Das Kursziel wird von $90 auf $72 reduziert. Zudem haben die Analysten die Gewinnschätzungen für 2005 von $2,75 auf $2,6 je Aktie und für 2006 von $2,7 auf $2,3 je Aktie gekürzt. Laut dem Analysten Yaron Werber besteht für Imclone die Gefahr, dass 6,5% der Verkaufserlöse von Erbitux an Lizenzinhaber abgeführt werden müssen. Frühere Schätzungen hatten sich auf lediglich 1,5% belaufen. Nach Ansicht von Werber ist dieser Faktor von den gegenwärtigen Wall-Street-Schätzungen nicht erfasst.
© BörseGo
66.040 -0.640 -0.96% Daily Commentary
WAITOur system recommends WAIT as of today. Previous SELL recommendation was made on 7/6/2004 (17) days ago, when the stock price was 83.960. Since then the stock fell -21.34% .
Today the stock closed lower with a lower high and a higher low (sign of decrease in volatility). The volume is high. The security price is trending down.
Click here to get a full trend analysis of this stock Candlestick Analysis
Today’s Candlestick Patterns:
Spinning Top
Today a Spinning Top formed. Both the bulls and the bears were active during the session. Even though the session opened and closed with little change, prices moved significantly higher and lower in the mean time. Be careful, this indicates weakness among the bears and a potential change or interruption in the current trend!
Stock Quote Last 66.040 Previous Close 66.680 Change -0.640 % Change -0.96% Volume 5,007,432 Stock Activity Open 66.480 Day's High 67.160 Day's Low 65.320 52 Week High 86.790 52 Week Low 32.740 Stock Price History 3 Month % Change -6.06 6 Month % Change 52.13 12 Month % Change 77.05 Stock Statistics 50 Day Close MA 77.307 200 Day Close MA 52.937 65 Day Volume MA 4,119,884 rnum=Math.round(Math.random() * 100000);document.write('');
sollte oben ein Fragezeichen sein!
45 Put fällig im Sep
26.07.04 21:26 Uhr0,09 EUR+181,25 % [+0,058]Typ:Put-OSBasiswert:Börse: LT Goldman Sachs
IMCLONE SYSTEMS INC. Registered S..WKN: GS8PUL
Chart verkleinernWeiter Seite 1/4
Ein unbekanntes aber offensichtlich zahlungskräftiges internationales Konsortium möchte die Steuerschulden des vor dem Bankrott stehenden Ölkonzerns Yukos vollständig übernehmen sowie die Hälfte der Aufsichtsratsposten einschließlich der Position des Vorsitzenden zu Gunsten des Staates abtreten.
Im Auftrag des Konsortiums unterzeichnete George Miller, Vorstand von International Waste Management Systems, einen entsprechenden Brief an Präsident Putin. Experten geben dem Rettungsversuch allerdings wenig Chancen.
Im Gegenzug erwartet das Konsortium eine Übertragung der Anteile des inhaftierten Oligarchen Chodorkowski. Offiziell sollen die Aktien ohne eine Entschädigung übertragen werden. Allerdings vermutet man, dass im Hintergrund geheime Zahlungen ablaufen sollen, die nicht offensichtlich gemacht werden dürfen. Chodorkowski und seine Mitgesellschafter halten etwa 60,5 Prozent an Yukos, Chodorkowski alleine etwa 40 Prozent. Alle Aktiva sind jedoch seit Monaten eingefroren.
Wie viele Investoren der Gruppe angehören und wie diese die für das Geschäft erforderlichen Gelder aufbringen wollen, blieb vorerst im Dunkeln. Die wichtigste Persönlichkeit in dem Konsortium sei der ehemalige Yukos-Minderheitsaktionär Konstantin Kagalowski, der jetzt in Großbritannien lebe.
Weiter
--------------------------------------------------
Autor: Regina Kaffl
Wie sollte das auch funktionieren? Warum sollte Chodorkowsky dazu einwilligen.
Welcher Geschäftsmann käme auf solch eine verrückte Idee?
Man kann sich leicht vorstellen wer die Fäden im Hintergrund gezogen hat!
Aktuell wieder plus 5 %
Fairer Wert beträgt 68,72$ aktuell 56,42!$
Price: IMCL closed on 7/26/2004 at $56.42 per share
Value: Value is a measure of a stock's current worth. IMCL has a current Value of $68.72 per share. Therefore, it is undervalued compared to its Price of $56.42 per share. Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitably increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.
RV (Relative Value): RV is an indicator of long-term price appreciation potential. IMCL has an RV of 1.43, which is excellent on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.
RS (Relative Safety): RS is an indicator of risk. IMCL has an RS rating of 0.71, which is poor on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.
RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. IMCL has a Relative Timing rating of 0.43, which is very poor on a scale of 0.00 to 2.00. RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.
VST (VST-Vector): VST is the master indicator for ranking every stock in the VectorVest database. IMCL has a VST rating of 0.91, which is fair on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price. The efficacy of this indicator was demonstrated in a study conducted at the University of Chicago which showed that high VST stocks outperformed the S&P 500 by 583.1% over the six year period from 1996 through 2002.
CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. IMCL has a CI rating of 0.84, which is poor on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.
GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. IMCL has a forcasted Earnings Growth Rate of 40.00%, which VectorVest considers to be excellent. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (9.18%).
Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. IMCL has a Sell recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.
Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position. IMCL has a Stop of $65.96 per share. This is $9.54 above IMCL's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.
EPS (Earnings per Share): EPS stands for leading 12 months Earnings Per Share. IMCL has a forecasted EPS of $2.14 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.
P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings. IMCL has a P/E of 26.36. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 29.19. P/E is computed daily using the formula: P/E = Price/EPS.
EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. IMCL has an EY of 3.79 percent. This is above the current average of 3.41% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).
GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. IMCL has a GPE rating of 1.52. High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 5.88%, the operative GPE ratio is 0.35. Therefore, IMCL may be considered to be undervalued.
DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. IMCL does not pay a dividend.
DY (Dividend Yield): DY reflects earnings per share as a percent of Price. IMCL does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.
DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. IMCL does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.
DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. IMCL does not pay a dividend, so it does not have a Dividend Growth rating .
YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. IMCL does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.
Open: IMCL opened trading at a price of $62.11 per share on 7/26/2004.
High: IMCL traded at a High price of $62.88 per share on 7/26/2004.
Low: IMCL traded at a Low price of $54.94 per share on 7/26/2004
Close: IMCL closed trading at price $56.42 per share on 7/26/2004. (Close is also called Price in the VectorVest system)
Range: Range reflects the difference between the High and Low prices for the day. IMCL traded with a range of $7.94 per share on 7/26/2004.
$Change: IMCL closed down 9.62 from the prior day's closing Price.
%PRC: IMCL's Price changed -14.57% from the prior day's closing price.
Volume: IMCL traded 20,157,200 shares on 7/26/2004.
AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. IMCL has an AvgVol of 4,259,000 shares traded per day.
%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals 100 x (Volume/AvgVol). IMCL had a %Vol of 373.28% on 7/26/2004
Sales: IMCL has annual sales of $224,000,000
Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. IMCL has a Sales Growth of 460.00% per year. This is excellent. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.
Sales Per Share (SPS): IMCL has annual sales of $2.97 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.
Price to Sales Ratio (P/S): IMCL has a P/S of 18.99. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.
Shares: IMCL has 75,000,000 shares of stock outstanding.
Market Capitalization: IMCL has a Market Capitalization of $4,264,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.
Industry Group: IMCL has been assigned to the Drug (BiomedicalGenetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
Business Sector: IMCL has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
The basic strategy of VectorVest is to buy Low risk, High reward stocks. We suggest that Prudent investors buy enough High Relative Value, High Relative Safety stocks to keep the overall RV and RS ratings of their portfolios above 1.00. As you do this, you'll find that your risk will go down and your investment performance will improve.
Graph
Imclone Sys
Drug (BiomedicalGenetic)
NEW YORK, Jul 29, 2004 (BUSINESS WIRE) -- ImClone Systems Incorporated
(NASDAQ: IMCL) announced today that Daniel S Lynch, Chief Executive Officer, is
scheduled to present at the 2004 Banc of America Specialty Pharmaceuticals
Conference in Southampton, NY on Friday, July 30, 2004, at 10:15 AM Eastern
Time. An informal Q&A session with the analyst and audience will follow a brief
introduction by Mr. Lynch.
The presentation will be webcast live and may be accessed by visiting ImClone
Systems' website at www.imclone.com. A replay of the webcast will also be
available immediately after the conclusion of the presentation. Investors can
access the webcast under "Presentations" in the "Investor Relations" section of
ImClone System's website.
About ImClone Systems Incorporated
ImClone Systems Incorporated is committed to advancing oncology care by
developing and commercializing a portfolio of targeted biologic treatments
designed to address the medical needs of patients with a variety of cancers. The
Company's three programs include growth factor blockers, angiogenesis inhibitors
and cancer vaccines. ImClone Systems' strategy is to become a fully integrated
biopharmaceutical company, taking its development programs from the research
stage to the market. ImClone Systems' headquarters and research operations are
located in New York City, with additional administration and manufacturing
facilities in Branchburg, New Jersey.
Certain matters discussed in this news release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995 and the Federal securities laws. Although the company believes that the
expectations reflected in such forward-looking statements are based upon
reasonable assumptions, it can give no assurance that its expectations will be
achieved. Forward-looking information is subject to certain risks, trends and
uncertainties that could cause actual results to differ materially from those
projected. Many of these factors are beyond the company's ability to control or
predict. Important factors that may cause actual results to differ materially
and could impact the company and the statements contained in this news release
can be found in the company's filings with the Securities and Exchange
Commission, including quarterly reports on Form 10-Q, current reports on Form
8-K and annual reports on Form 10-K. For forward-looking statements in this news
release, the company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation Reform
Act of 1995. The company assumes no obligation to update or supplement any
forward-looking statements, whether as a result of new information, future
events or otherwise.
SOURCE: ImClone Systems Incorporated
CONTACT: ImClone Systems Incorporated
Andrea F. Rabney, 646-638-5058
or
Stefania Bethlen, 646-638-5058
Customize your Business Wire news & multimedia to match your needs.
Get breaking news from companies and organizations worldwide.
Logon for FREE today at www.BusinessWire.com.
Copyright (C) 2004 Business Wire. All rights reserved.
KEYWORD: NEW YORK NEW JERSEY
INDUSTRY KEYWORD: PHARMACEUTICAL
MEDICAL
BIOTECHNOLOGY
TRADESHOW
http://www.imclone.com/content.php?pg=calendar.html
2004 CALENDAR OF EVENTS
INVESTOR CONFERENCES
Back to Top
SCIENTIFIC MEETINGS
ConferenceDateLocation American Association for Cancer Research (AACR) Annual Meeting Apr 5 - Apr 9 Toronto, Ontario, Canada American Society of Clinical Oncology (ASCO) Annual Meeting May 31 - Jun 3 Chicago, IL 3rd Annual International Symposium on Translational Research in Oncology Jul 15 - Jul 21 Dublin, Ireland 3rd International Congress on Monoclonal Antibodies in Cancer Aug 14 - Aug 17 Quebec, Canada 2nd International Congress on Targeted Therapies in Cancer Aug 29 - Aug 31 Washington, D.C. Chemotherapy Foundation Symposium XXI: Innovative Cancer Therapy for Tomorrow 1972 - 2003 Nov 12 - Nov 15 New York, NY AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics Nov 17 - Nov 21 Boston, MA Antibody Production and Downstream Processing: Creating Successful Antibody-Based Biopharmaceutical ProductsFeb 25 - 27San Diego, CAAACR 95th Annual MeetingMar 27 - 31Orlando, FLCambridge Healthtech Institute's Fifth Annual Recombinant AntibodiesApr 28 - 29Cambridge, MAPharmaceutical Research and Manufacturers of America 2004 Biologics & Biotechnology Committee Spring MeetingMay 24 - 26Washington, D.C.ASCO 40th Annual MeetingJun 05 - 08New Orleans, LAAnti-Cancer Drug Discovery & Development Summit 2004Jul 21 - 23Philadelphia, PAIBC's 9th Annual World Congress - Drug Discovery Technology 2004Aug 08 - 13Boston, MAAdvances in Cancer Therapies 2004Sep 15 - 16London, England
Back to Top Investor Conferences
Scientific Meetings
Company Overview | Clinical Programs | Research | News | Investor Relations | Calendar | Careers
©
Jul 30, 2004 (streetinsider.com via COMTEX) -- Bristol-Myers Squibb Company
(NYSE: BMY) announced that it has reached an agreement to settle its securities
class action lawsuit, which is pending in the U.S. District Court in the
Southern District of New York against the company and a number of the company's
current and former officers, related to wholesaler inventory and other
accounting matters, and the company's investment in and relationship with
ImClone Systems Inc., and ImClone's product, ERBITUX. Under the proposed
settlement, the litigation will be terminated in exchange for a payment of $300
million. As part of the settlement, the company made no admission of wrongdoing.
StreetInsider.com Premium is also available to Bloomberg Terminal users.
Bloomberg users type STIN for more information.
| COLUMN: House arrest not an equal punishment |
AUSTIN, Texas, Jul 30, 2004 (Daily Texan, U-WIRE via COMTEX) -- On Wednesday,Martha Stewart offered to begin the house arrest portion of her sentence in herBedford, N.Y., home while awaiting the results of her appeal.Stewart was convicted for conspiracy, obstruction of justice and making falsestatements to federal investigators about her sale of ImClone Systems Inc. stockin December 2001. The sale occurred the day before the FDA denied approval for acancer drug, causing stocks to drop. The drug has since been approved, and thestock is higher than the value Stewart sold them for.Stewart has been sentenced to five months in prison, five months of housearrest, two years of probation and a $30,000 fine, the minimum sentence allowedby federal guidelines. U.S. District Judge Miriam Goldman Cedarbaum said thatshe gave Stewart the minimum sentence because she felt that Stewart had"suffered and will continue to suffer enough." It seems as though the judge hasconstrued bad press as legally punitive.Since the creation of the Justice Department's Corporate Fraud Task Force in2001, at least 25 former chief executive officers have been charged or convictedof fraud through federal prosecution. This has led others to feel that Stewarthas been treated harshly, a victim of the department's prosecution ofwhite-collar crime. Congress has asked the task force to pursue obstructiveconduct, indicating a pressure to prosecute Stewart.However, many feel that Stewart has received star treatment, with 16 months inprison as the maximum sentence for her conviction.This is why sentencing guidelines exist: To help prevent special treatment.Stewart's sentence falls within the range mandated, but five months of housearrest on a 153-acre estate in Bedford hardly seems to be more than a slap onthe wrist when compared to five months in prison.Sentencing guidelines exist to ensure that defendants receive roughly equalsentences nationwide, without regard to personal status. However, a 153-acreestate that cost almost $16 million when purchased is not the same as a prison,or even a three-bedroom home.Stewart will either be required to wear a bracelet with a set radius or havecheck-in times; but the area surrounding her will be nicer than the averageAmerican neighborhood. The quality of life Stewart will live is markedlydifferent from the average American, either at home or in jail. The existence ofhouse arrest creates an inequality which sentencing guidelines have notremedied.In the Sarbanes-Oxley Act of 2002, Congress noted that the sentencing guidelinesfor white-collar crime needed to be made harsher. In January 2003 the sentencingcommission voted to increase penalties for both corporate fraud and obstructionof justice related to corporate fraud investigations. The use of house arrestfor white-collar criminals seems to go against this public directive.This is not to say that house arrest does not serve a purpose in society: It issometimes necessary to order murder suspects to remain under house arrest whileawaiting trial. It makes sense to require this when a suspect is potentiallydangerous. However, once a conviction has been established, the use of housearrest creates an inequality in punishment, as not everyone's home is the same.By Katie Turnerhttp://www.dailytexanonline.com |
August 03, 2004 10:01 PM Berlin Timezone  ImClone Systems Incorporated Receives $5 Million Equity Milestone Payment from Merck KGaA Relating to European Commission Approval of ERBITUX-TM- NEW YORK--(BUSINESS WIRE)--Aug. 3, 2004--ImClone Systems Incorporated (NASDAQ:IMCL) announced today that it has received a cash payment of $5 million as a result of its achieving a milestone in its license agreement with Merck KGaA of Darmstadt, Germany, for development of ERBITUX(TM)(Cetuximab), an IgG1 monoclonal antibody, outside of North America. The milestone relates to the European Commission approval of ERBITUX for the treatment of patients with metastatic, EGFR-expressing colorectal cancer after failure of irinotecan-including cytotoxic therapy. Upon payment, ImClone Systems issued 58,807 shares of ImClone Systems' common stock to Merck KGaA, representing the sale of these shares at a ten percent premium to market value as provided in the license agreement. "This payment is the final milestone-based payment from Merck KGaA under our ERBITUX license agreement and it underscores the achievements of our partnership to date," said Daniel S. Lynch, Chief Executive Officer of ImClone Systems. "Thanks to the efforts of all three companies involved in the development of ERBITUX, ImClone Systems, Merck KGaA and Bristol-Myers Squibb, this antibody is now available to many thousands of patients with late stage colorectal cancer throughout Europe and the Americas. We look forward to an enduring collaboration with our partners as we work to maximize ERBITUX's clinical and regulatory potential around the world." ERBITUX is the first monoclonal antibody specifically targeting the epidermal growth factor receptor (EGFR) to gain marketing authorization in Europe. It will be available in all 25 member states of the newly expanded European Union as well as Iceland and Norway according to local legal regulations for supply. Merck KGaA of Darmstadt, Germany, received the approval for ERBITUX from the European Commission based on the company's European clinical trial that included more than 300 patients. In December 1998, Merck KGaA licensed from ImClone Systems the right to develop ERBITUX outside of the U.S. and Canada and the co-exclusive right to develop ERBITUX in Japan. About ERBITUX(TM) (Cetuximab) ERBITUX is approved by the FDA for use in combination with irinotecan in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy. The effectiveness of ERBITUX for the treatment of colorectal cancer is based on objective response rates. Currently, no data are available that demonstrate an improvement in disease-related symptoms or increased survival with ERBITUX. Outside the U.S., Merck KGaA of Darmstadt, Germany, gained approval for use of ERBITUX in combination with irinotecan in patients with EGFR-expressing metastatic colorectal cancer who have failed prior irinotecan therapy in Switzerland in December 2003. In May 2004, ERBITUX was also approved in Argentina and Mexico as well as in June 2004 in Chile, for use in combination with irinotecan or as a single agent in patients with EGFR-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. ERBITUX binds specifically to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) on both normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha. The EGFR is constitutively expressed in many normal epithelial tissues, including the skin and hair follicle. Over-expression of EGFR is also detected in many human cancers including those of the colon and rectum. About Colorectal Cancer In the U.S., approximately 147,000 people will be diagnosed with cancer of the colon or rectum this year. Half of these patients have metastatic disease, or cancer that has spread to other organs, at the time of diagnosis. EGFR is expressed in up to 77 percent of colorectal cancer tumors. Colorectal cancer is the second-leading cause of cancer death in the U.S. In Europe, colorectal cancer is the second most common malignancy after lung cancer in men and breast cancer in women. Almost half of the 260,000 people diagnosed with the disease each year in the EU have advanced cancer. ERBITUX Important Safety Information Severe infusion reactions, rarely fatal and characterized by rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), urticaria, and hypotension, have occurred in approximately 3% of patients with the administration of ERBITUX (Cetuximab). Most reactions (90%) were associated with the first infusion of ERBITUX. Caution must be exercised with every ERBITUX infusion as there were patients who experienced their first severe infusion reaction during later infusions. Severe cases of interstitial lung disease (ILD), which was fatal in one case, occurred in less than 0.5% of patients receiving ERBITUX. Dermatologic toxicities, including acneform rash (11% grade 3/4), skin drying and fissuring, inflammatory or infectious sequelae (e.g. blepharitis, cheilitis, cellulitis, cyst) and paronychial inflammation (0.4% grade 3) were reported. Sun exposure may exacerbate these effects. Other serious adverse events associated with ERBITUX in clinical trials were fever (5%), sepsis (3%), kidney failure (2%), pulmonary embolus (1%), dehydration (5% in patients receiving ERBITUX plus irinotecan, 2% receiving monotherapy) and diarrhea (6% in patients receiving ERBITUX plus irinotecan, 0.2% with monotherapy). Additional common adverse events seen in patients receiving ERBITUX plus irinotecan (n=354) or ERBITUX monotherapy (n=420) were acneform rash (88%/90%), asthenia/malaise (73%/48%), diarrhea (72%/25%), nausea (55%/29%), abdominal pain (45%/26%), vomiting (41%/25%), fever (34%/27%), constipation (30%/26%) and headache (14%/26%). Full prescribing information is available upon request, or at www.ERBITUX.com. About ImClone Systems Incorporated ImClone Systems Incorporated is committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's three programs include growth factor blockers, angiogenesis inhibitors and cancer vaccines. ImClone Systems' strategy is to become a fully integrated biopharmaceutical company, taking its development programs from the research stage to the market. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey. Certain matters discussed in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the company's ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company's filings with the Securities and Exchange Commission including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. | |
|
die aktie ist klasse und wird ihren weg wieder machen, nur leider hilft das nix mehr für die inhaber, die die calls immer noch haben (so wie ich)...
also neue kaufen (längere).
Genentech Warning May Help ImClone
Matthew Herper, 08.13.04, 1:59 PM ET
NEW YORK - Genentech's much-hyped colon cancer medicine just hit a rough patch.
This morning, Genentech (nyse: DNA - news - people ) and the U.S. Food and Drug Administration issued a "dear doctor" letter to physicians stating that the biotech's breakthrough colon cancer drug Avastin may increase the risk of heart attack, stroke and other cardiovascular problems. Genentech fell 5% to $44.63 on the news. The letter is signed by Hal Barron, Genentech's chief medical officer.
"Patients who experience an arterial thromboembolic event during treatment should permanently discontinue Avastin," Barron warned.
In a note to investors, Bernstein sell-side biotech analyst Geoffrey Porges noted that Genentech's clinical trials for Avastin, presented at the meeting of the Annual Society for Clinical Oncology last May, had excluded patients with a previous history of cardiovascular disease. It's possible, he suggests, that the FDA is seeing problems spring up in patients who were already at risk. Porges, who has a "Market Perform" rating on Genentech, also wrote that heart side effects are not surprising given that Avastin can cause hypertension, which itself ups the risk of heart attack and stroke.
The side effect may not have a big impact on sales, he noted, because Avastin is approved for colon cancer that has already spread to other parts of the body. This is itself a fatal disease, with a median survival of 20 months. Avastin extends life in these colon cancer patients. Winton Gibbons, an analyst at William Blair & Co., wrote in a research note that he still views Genentech as his top pick in the biotech space over the next three to five years. However, Bernstein's Porges wrote, doctors may opt to use ImClone Systems' (nasdaq: IMCL - news - people ) competing colon cancer drug Erbitux instead in some of their sickest patients. ImClone shares are up almost 1% to $54.61.
Both Avastin and Erbitux are biotech drugs that must be given intravenously. Both have been criticized for their incredibly high price. If these side effects cause marketing problems down the road for Genentech, it could be because cheaper-to-administer cancer pills now in clinical development turn out to provide some of the same benefits without as much heart risk. Pfizer (nyse: PFE - news - people ), Novartis (nyse: NVS - news - people ) and GlaxoSmithKline (nyse: GSK - news - people ) are among the drug giants looking to develop cancer pills that work at least in part by hitting the same protein blocked by Avastin.
+
(©GodmodeTrader - http://www.godmode-trader.de/)
Smith Barney Citigroup stufen ImClone Systems erneut mit "hold" und Kursziel $72 ein. Laut den Investmentbankern haben die Verschreibungen im Juli für ImClone`s Krebsmedikament Erbitux ein über 10%iges Wachstum ausgewiesen. In den vergangenen drei Monaten hätten die Verschreibungen ein durchschnittliches Wachstum von 19% für jenes Mittel indiziert. Aufgrund des positiven Trends bei Erbitux zeigen die Analysten Zuversicht, dass ImClone im dritten Quartal wie erwartet $90 Mio und im Gesamtjahr $282 Mio erlösen wird. Die Experten führen aber an, dass Lizenzzahlungen des Unternehmens als Risikofaktoren für dessen Gewinnsituation anzusehen sind.
Da ich nicht so gut Englisch lesen kann suche ich Deutsche News von Heute Mittag,glaube
die News ist gut haben neue Zulassung bekommen.Aber der Kurs Fällt wieso?
und Sell on good News.
Außerdem sind die Nachrichten evtl. schon eingepreist, im Kurs.
Mein grundsatz: handle nie gegen den Chart, auch wenn die News noch so gut sind.
Hab den Chart aber im Auge, bzw. den Kurs.
Der chart sagt:
IMCLONE SYSTEMS INC - Nasdaq National Market: IMCL
Charts provided by TelescanMacd, zeigt nach unten,
Die Aktie ist überkauft
Momentum zeigt nach unten, sieht man bei diesem Bild nicht so gut, ist aber so
ROC auch,
drum Kursrückgang.
gruß
gs